Posted on: October 24, 2019 Posted by: earlenehands Comments: 0

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda



Dr. Jänne, Director, Lowe Center for Thoracic Oncology, Director, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine, Harvard Medical School, shares how he would treat 2nd line patients who previously received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy

source: https://medinaportal.net

Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Categories:

Leave a Comment